DMARDs and Biologics for Rheumatoid Arthritis

If you have just been handed a prescription for methotrexate, you have probably already read something frightening about it. Perhaps that it is a chemotherapy drug. Perhaps that it will wreck your liver. Perhaps that the whole category of these medications simply suppresses symptoms while the "real cause" goes unaddressed. Those worries deserve a straight answer rather than a lecture, and this page tries to give one.

Here is the honest version. Rheumatoid arthritis is not a wear-and-tear problem and it is not primarily a pain problem. It is an immune system that has begun manufacturing an inflamed, invasive tissue inside your joints — a growth called pannus — which recruits bone-dissolving cells and chews holes in the bone at the joint margin. Those holes are called erosions, and they do not fill back in. Cartilage does not regrow. A tendon that ruptures because inflamed synovium wore through it does not re-knit. This is the single fact that organises everything else on this page: the damage is cumulative and permanent, and the clock is running while you decide.

Disease-modifying antirheumatic drugs — DMARDs — are the class of medicines that demonstrably stop or slow that process. Not "reduce pain scores." Stop the erosion count from climbing on serial X-rays. That is a different and much higher bar, and it is a bar that anti-inflammatory diets, fish oil, turmeric, and exercise have not cleared, however genuinely useful those things are for how you feel day to day. This page explains what each drug does, what it costs you in risk and inconvenience, and where the natural approaches you may already be using still belong. The canonical Rheumatoid Arthritis page covers diagnosis, antibodies, and the disease itself; this page is about the treatment decision.

Table of Contents

1. The Window of Opportunity
2. Treat-to-Target: The Strategy Beats the Drug
3. Methotrexate: The Anchor Drug
4. Methotrexate: The Real Side-Effect Picture
5. The Other Conventional DMARDs, and Triple Therapy
6. Biologics: One Signal Instead of the Whole System
7. JAK Inhibitors and the Safety Signal That Changed the Rules
8. Corticosteroids: A Bridge, Not a Destination
9. Infection Risk, Screening and Vaccination
10. Tapering and Drug-Free Remission
11. Where Diet, Supplements and Exercise Actually Fit
12. Questions Worth Asking at Your Appointment
13. Key Research Papers
14. Connections
15. Featured Videos

The Window of Opportunity

Rheumatology has a phrase for the early phase of the disease: the window of opportunity. The idea is that in the first months after symptoms begin, the immune response is still comparatively plastic — not yet locked into the self-sustaining loops that make established disease so stubborn. Treat inside that window and you get more remissions, deeper remissions, and less structural damage. Treat outside it and you are fighting a more entrenched opponent with the same weapons.

A systematic review of this question found that patients treated earlier did better on both disease activity and radiographic outcomes, and that the advantage was not simply explained by treating milder disease. What the literature has never done is agree on where exactly the window closes. Different studies draw the line at three months, six months, twelve. That disagreement is actually reassuring in one respect: it means there is no cliff edge you have already fallen off. It is a gradient, and earlier is better all along it.

The practical consequence is unglamorous. The biggest single determinant of your long-term joint outcome is often not which DMARD you take but how many months passed between your first swollen joint and your first effective dose. Delays accumulate quietly: a few months attributing it to overuse, a few more waiting on a referral, a few more trying an elimination diet first to see whether that fixes it. Each of those is a reasonable decision in isolation. Together they can spend the window.

This is also why rheumatologists start treatment before the diagnosis is airtight. If you have persistent swelling in several small joints, a positive anti-CCP antibody, and a raised CRP, waiting six more months for diagnostic certainty costs more than it buys. The lab tests support the decision; they rarely make it alone.

Treat-to-Target: The Strategy Beats the Drug

Here is one of the more surprising findings in the field: how the treatment is steered matters as much as what the treatment is.

The old model was to start a drug, see the patient in six months, and adjust if they were still complaining. The treat-to-target model sets a numerical goal — remission, or at minimum low disease activity — measures against it every one to three months, and escalates therapy whenever the target is not met. No waiting to see. No "let's give it another year."

The TICORA trial tested exactly this. Two groups, the same drugs available to both; one got monthly assessments with protocol-driven escalation, the other got routine care. The intensively managed group did dramatically better on disease activity, physical function, quality of life, and radiographic progression, with several times as many patients reaching remission. Nothing exotic was used. The difference was the discipline of measuring and acting. A later systematic review of the treat-to-target evidence reached the same conclusion across multiple trials.

The score most often used is the DAS28, which combines a count of tender joints, a count of swollen joints, an inflammatory blood marker (ESR or CRP), and your own global rating of how you are doing on a 0–100 line. Other clinics use CDAI or SDAI. The number is crude, and it can be pushed around by fibromyalgia-type pain that is not inflammatory at all — but a crude number that gets acted on every eight weeks beats a sophisticated impression that gets acted on annually.

What this means for you as a patient is concrete: if you are three months in and still clearly not well, that is information, not failure. It is the signal to change something. Patients often sit quietly on an inadequate regimen because they do not want to seem demanding or because they assume this is as good as it gets. Say the number out loud at your appointment.

Methotrexate: The Anchor Drug

Almost every treatment pathway in rheumatoid arthritis starts here, and most keep methotrexate in the background even after other drugs are added. Both the American College of Rheumatology and EULAR name it the first choice for nearly all newly diagnosed patients.

The chemotherapy question, answered. Yes, methotrexate is used in oncology. At doses one to two orders of magnitude higher than yours, given intravenously, for a completely different purpose. In rheumatoid arthritis it is a low-dose weekly immunomodulator, and its main anti-inflammatory action is thought to run through adenosine signalling rather than the anti-folate cell-killing effect that matters in cancer. Comparing the two is like comparing a glass of wine to industrial solvent on the grounds that both contain alcohol. Hair falling out in handfuls, and the profound drop in white cells that oncology dosing causes, are not what 15 mg a week does — blood counts can still drift down on this dose, which is precisely why they are monitored, but the side-effect profile is an entirely different animal.

Dosing. Methotrexate is taken once a week, not daily. This is the single most important sentence about it. Daily dosing by mistake has killed people, which is why pharmacies label it aggressively and why many rheumatologists ask you to name the day out loud. Typical practice is to start in the region of 10–15 mg weekly and escalate over the following weeks toward 20–25 mg weekly, because underdosing is a common reason the drug appears to "not work." Give it time as well as dose: methotrexate is slow, and meaningful benefit usually takes six to twelve weeks to appear.

Tablets or injection. If oral methotrexate causes nausea, or if you are not responding at a full oral dose, the subcutaneous form is a genuine option rather than a consolation prize. Absorption of oral methotrexate plateaus at higher doses; injecting bypasses that ceiling. A randomised double-blind trial comparing the two routes at the same dose found subcutaneous administration more effective, without a meaningful increase in adverse effects. Many people also find the injection settles the gut symptoms.

Folic acid is not optional. Methotrexate interferes with folate metabolism, and most of its everyday nuisance effects — mouth ulcers, nausea, abnormal liver enzymes — track that interference. A Cochrane review of folic and folinic acid supplementation in patients taking methotrexate for rheumatoid arthritis found substantial reductions in gastrointestinal side effects and liver enzyme abnormalities, and fewer people abandoning the drug because of side effects. Common regimens are 5 mg once weekly taken a day or two after the methotrexate, or 1 mg daily except on methotrexate day. Take it. If nobody prescribed it, ask why. See also Folate (Vitamin B9).

Monitoring. Blood tests — full blood count, liver enzymes, and kidney function — are checked frequently at the start and after any dose increase, then settle into a routine interval of roughly every two to three months once you are stable. This is not defensive box-ticking. Almost every serious methotrexate problem announces itself in bloodwork before it announces itself in symptoms, which is precisely why the monitoring makes the drug safe to use for decades. Kidney function matters especially, because methotrexate is cleared renally and a decline in kidney function turns a previously fine dose into a toxic one.

Two drug interactions worth memorising. The dangerous one is trimethoprim, whether on its own or as co-trimoxazole (trimethoprim–sulfamethoxazole, sold as Bactrim or Septrin). It is a folate antagonist in its own right, and combined with methotrexate it has caused severe and occasionally fatal bone-marrow failure. If a walk-in clinic, dentist or out-of-hours doctor offers it for a urinary or chest infection, say clearly that you take weekly methotrexate and ask for an alternative. The second is subtler: anything that reduces kidney clearance pushes methotrexate levels up. That includes regular high-dose NSAIDs, some proton pump inhibitors, and simple dehydration during a vomiting illness. None of these is an absolute ban — plenty of people take an NSAID alongside methotrexate under supervision — but they belong on the list you hand over at every appointment, and a week of gastroenteritis is a good reason to ring your team before taking the next dose.

Methotrexate: The Real Side-Effect Picture

A Cochrane review of methotrexate versus placebo in rheumatoid arthritis confirmed both halves of the story: clear benefit over placebo on disease activity, and more people stopping the drug because of adverse events. Both are true. Here is what patients actually report, in rough order of frequency.

Pregnancy and contraception. Methotrexate causes birth defects and pregnancy loss. Anyone who could become pregnant needs reliable contraception for the whole time they are on it, and it must be stopped before conception — published advice for the person who will carry the pregnancy ranges from at least one full ovulatory cycle to three months, so ask your rheumatologist to name the interval rather than guessing. It should not be taken while breastfeeding, because it passes into breast milk. Advice to prospective fathers has become less restrictive as the data have accumulated, but it is still a question to ask rather than assume. Raise pregnancy plans at the very first appointment, because they change the whole drug selection: sulfasalazine, hydroxychloroquine and certolizumab are the usual pregnancy-compatible options. Leflunomide sits under the same prohibition as methotrexate and needs a cholestyramine washout before conception, because it lingers for many months on its own.

The alcohol question — the honest answer. For years the instruction was blanket abstinence, which many patients quietly ignored, which meant nobody was having an accurate conversation about it. A large study using primary care records quantified the actual risk of liver enzyme elevation across levels of weekly alcohol intake in rheumatoid arthritis patients taking methotrexate. The pattern was dose-dependent rather than all-or-nothing: no significant excess risk at modest intakes, with risk rising as weekly consumption increased, and clearly elevated at heavy intake. The reasonable reading is that an occasional drink is not the catastrophe it was once described as, that regular heavy drinking genuinely is dangerous on this drug, and that this is a conversation to have honestly with your rheumatologist rather than a rule to break in secret. If you have fatty liver, hepatitis B or C, or any other liver disease, the calculus is stricter — see Nephrology & Hepatology.

The Other Conventional DMARDs, and Triple Therapy

Methotrexate is the anchor, but it is not the only conventional synthetic DMARD, and the others are not merely leftovers for people who cannot tolerate it.

Triple therapy means all three of methotrexate, sulfasalazine and hydroxychloroquine together. It is unfashionable, it involves swallowing a lot of tablets, and it is remarkably effective. In the RACAT trial, patients whose disease was still active on methotrexate were randomised to add either triple therapy or a TNF inhibitor. Triple therapy was non-inferior. In the TEAR trial, immediate triple therapy and immediate methotrexate-plus-etanercept produced similar disease activity outcomes, with only modest radiographic differences.

This matters for two kinds of reader. If cost or insurance is a barrier to biologics — and for many people it is the decisive barrier — triple therapy is not a second-class fallback, it is an evidence-backed alternative. And if you would simply rather stay on older, longer-studied drugs, that preference is compatible with good outcomes. The EULAR recommendations and the ACR guideline both keep conventional DMARD combinations on the map.

The BeSt study made a related point from a different angle: it compared four treatment strategies in early disease and found that starting with combination therapy from the outset produced faster functional improvement and less radiographic damage than climbing a ladder one drug at a time. Being aggressive early is not the same as being reckless.

Biologics: One Signal Instead of the Whole System

Conventional DMARDs are blunt instruments — they dial down immune activity broadly. Biologics are proteins engineered to intercept one specific molecule or cell population. Think of the difference between turning down the volume on the whole stereo and muting one instrument in the orchestra.

They are given by injection under the skin or by infusion, because they are large proteins that stomach acid would destroy. They are expensive, although biosimilars have brought prices down substantially in most markets. They are generally added to methotrexate rather than replacing it, partly because the combination works better and partly because methotrexate reduces the formation of antibodies against the biologic itself.

TNF inhibitors

Tumour necrosis factor is a master inflammatory signal, and blocking it was the breakthrough that changed rheumatology in the late 1990s. Five are in wide use: etanercept (a decoy receptor that mops up circulating TNF), and adalimumab, infliximab, golimumab and certolizumab (antibodies that bind it). They are usually tried first among biologics, and biosimilar versions have made them the cheapest option in the class.

Differences worth knowing: etanercept is generally less effective for granulomatous conditions and for the eye and bowel inflammation that can accompany rheumatic disease, so if you also have uveitis or inflammatory bowel disease, a monoclonal antibody is usually preferred. Certolizumab crosses the placenta minimally, which makes it a common choice in pregnancy. Infliximab is infused and dosed by weight; the others are self-injected pens or syringes, although golimumab also has an intravenous form.

IL-6 receptor blockade

Tocilizumab and sarilumab block the interleukin-6 receptor. IL-6 drives not only joint inflammation but also the systemic features of rheumatoid arthritis — anaemia of chronic disease, fatigue, fever, and the acute-phase response itself.

The ADACTA trial compared tocilizumab monotherapy against adalimumab monotherapy in patients for whom methotrexate was unsuitable, and found tocilizumab superior. That is an unusually specific and useful result: if you cannot take methotrexate, IL-6 blockade is the class with the best evidence for going it alone.

Two quirks. First, because IL-6 drives CRP production, this drug normalises your CRP whether or not it has controlled your disease — so CRP stops being a useful monitoring test, and infections can be under way without the usual blood-marker warning. Second, it raises cholesterol, lowers neutrophils, can raise liver enzymes, and carries a small but real risk of bowel perforation that is concentrated in people with diverticular disease.

T-cell costimulation blockade — abatacept

Abatacept is a fusion protein that works further upstream than anything else in the toolkit. T cells need two signals to activate: recognition of an antigen, and a second "go ahead" handshake between CD28 on the T cell and CD80/CD86 on the antigen-presenting cell. Abatacept occupies CD80/CD86 and withholds the handshake, so the T cell sees the antigen but never gets switched on.

The AIM trial established its efficacy in patients whose disease remained active on methotrexate. In practice it tends to work best in patients who are anti-CCP positive, and it is often selected for people with a history of interstitial lung disease or of malignancy, where its safety profile is comparatively reassuring. It is given as a weekly self-injection or a monthly infusion.

B-cell depletion — rituximab

Rituximab is an antibody against CD20, a marker on B cells. It removes circulating B cells almost completely for months at a time. The REFLEX trial demonstrated its efficacy in patients whose disease was refractory to anti-TNF therapy, and it remains a mainstay in that setting.

It is dosed unlike anything else here: two infusions two weeks apart, then nothing at all until the disease returns or a scheduled repeat around six months later. For people who hate weekly injections, that rhythm is a genuine advantage. It works best in seropositive disease (rheumatoid factor or anti-CCP positive). The trade-offs are that immunoglobulin levels can fall over repeated cycles, and vaccine responses are markedly blunted for months afterwards — which is why vaccination timing around rituximab is planned rather than improvised.

JAK Inhibitors and the Safety Signal That Changed the Rules

Janus kinase inhibitors — tofacitinib, baricitinib, upadacitinib, filgotinib — are small molecules you swallow. They work inside the cell, blocking the JAK-STAT relay that many inflammatory cytokines use to transmit their message to the nucleus. Because they interrupt the shared wiring rather than one signal, they are broad and fast: patients often report improvement within a fortnight, which is unusual in this field. The RA-BEAM trial showed baricitinib superior to placebo on its primary endpoint and, on a prespecified secondary comparison, superior to adalimumab.

Then came ORAL Surveillance. Regulators had required a dedicated safety trial of tofacitinib in a deliberately higher-risk population — patients aged 50 and over with at least one cardiovascular risk factor — compared against a TNF inhibitor. The trial failed to demonstrate non-inferiority: the tofacitinib groups had more major adverse cardiovascular events and more cancers than the TNF-inhibitor comparator, along with more venous blood clots. Later analyses suggested the excess was concentrated in older patients and in people who had ever smoked, rather than spread evenly across everyone taking the drug.

Regulators responded by extending the warnings to the whole class rather than to tofacitinib alone. In the United States the FDA narrowed the labelled position of JAK inhibitors in rheumatoid arthritis to patients who have already had an inadequate response to one or more TNF inhibitors. In Europe the EMA left the position broader but said they should be used in people over 65, current or long-term former smokers, those with cardiovascular or cancer risk factors, and those with a history of blood clots only where no suitable alternative is available. Timing matters when you read the two guidelines cited below: the EULAR 2022 update was written after ORAL Surveillance and reflects it directly, while the ACR guideline was published in 2021, before the trial reached print — so its JAK-inhibitor positioning should be read alongside the later regulatory warnings, not instead of them.

How should a patient read this? Not as "JAK inhibitors are dangerous drugs." Read it as: this is a class where your personal risk profile changes the answer more than usual. A 42-year-old lifelong non-smoker with no cardiovascular history and disease that has resisted two biologics is in a very different position from a 70-year-old ex-smoker with treated hypertension. The convenience of a tablet is real, the speed of onset is real, and so is the signal. Ask specifically where you sit on that risk map.

One more class effect worth planning for: JAK inhibitors substantially increase the risk of shingles, more so than biologics do. A dedicated analysis of herpes zoster in tofacitinib-treated patients documented this, with the highest rates in Asian populations. The non-live recombinant zoster vaccine is the answer, and ideally it is given before you start.

Corticosteroids: A Bridge, Not a Destination

Prednisone works. That is exactly the problem. It works so quickly and so completely that it is easy to end up on it for years, which is where the harm lives.

The legitimate role is as a bridge: a short course, often at a modest dose, to get you functional during the eight to twelve weeks it takes methotrexate to reach full effect, or to break a flare. Used that way, tapering off as the DMARD takes hold, the risk is modest and the benefit is substantial. Intra-articular injection into one badly behaved joint is a similarly targeted use.

The illegitimate role is as a permanent substitute for disease-modifying treatment. Chronic glucocorticoid exposure buys you osteoporosis and fractures, cataracts and glaucoma, skin thinning and bruising, raised blood sugar and frank diabetes, weight gain and central fat redistribution, hypertension, adrenal suppression, and a dose-dependent increase in serious infection. Crucially, most of these accumulate with total lifetime exposure — there is no dose so low that it is free.

The GLORIA trial is instructive precisely because it studied the tempting scenario: adding a low daily dose of prednisolone long-term for older patients with rheumatoid arthritis. Over two years there was a genuine but modest benefit in disease activity and damage, bought with a measurable increase in adverse events, mostly infections. That is the trade in miniature. It is a defensible bargain for some people; it is not a free lunch for anyone.

If you are on steroids and have been for more than a few months, the useful question at your next appointment is not "can I come off?" but "what is the plan that makes coming off possible?" Usually the answer is a more effective DMARD regimen underneath. And never stop long-term steroids abruptly — the adrenal glands need a taper to restart. Bone protection, including vitamin D and adequate calcium, belongs in any long steroid course.

Infection Risk, Screening and Vaccination

Every drug on this page turns down some part of the immune system, and infection risk is the price. A Cochrane overview and network meta-analysis of biologics found an increased risk of serious infections and of tuberculosis reactivation compared with control. That is the honest headline. Two things put it in proportion: uncontrolled rheumatoid arthritis itself raises infection risk, and so do the steroids people take instead when disease is poorly controlled. The comparison is never "drug versus nothing" — it is "drug versus untreated inflammatory disease."

Screening before you start. The reason tuberculosis screening is mandatory before TNF inhibitors is a specific, historical, and rather dramatic one: TNF is what holds the granuloma together that walls off latent tuberculosis. Block it and the wall can come down. A landmark case series reported tuberculosis emerging in patients treated with infliximab, often extrapulmonary and often within months of starting — and that report is why every patient now gets an interferon-gamma release assay or tuberculin test plus a chest X-ray first. Hepatitis B and C serology are also checked, because immunosuppression can reactivate hepatitis B, sometimes severely.

Vaccination. The 2022 ACR vaccination guideline for rheumatic and musculoskeletal disease is the reference point here. The principles that matter most to you:

• Inactivated and recombinant vaccines are safe on these drugs. Influenza annually, pneumococcal, and the recombinant (non-live) shingles vaccine are all appropriate and actively recommended.
• Live vaccines are generally contraindicated while on biologics or JAK inhibitors — this includes the older live shingles vaccine, yellow fever, and MMR. Plan travel vaccination well in advance of starting therapy.
• Timing around rituximab matters enormously. Vaccinate before the infusion if at all possible; response is poor for months afterwards.
• Holding methotrexate briefly after influenza vaccination is conditionally recommended for patients with well-controlled disease, because it improves the antibody response. Do not improvise this — ask.

When to hold a dose. The general rule is to skip your DMARD or biologic while you have an active infection needing antibiotics, and to restart once it has resolved. Around planned surgery there are drug-specific holding schedules. Establish these rules with your team once, in advance, so you are not making the decision at 9 p.m. with a fever.

Tapering and Drug-Free Remission

This is the question almost every patient asks eventually: do I have to take this forever?

The truthful answer has three parts. First, sustained remission on treatment is now a realistic goal for a large proportion of patients, which was not true a generation ago. Second, tapering is legitimate and is built into the guidelines — you are not obliged to stay at maximum therapy forever once you are well. Third, complete drug-free remission is uncommon, and attempting it carries a real relapse risk.

The RETRO study randomised patients in stable remission to continue treatment unchanged, taper to half dose, or stop entirely. Relapses increased stepwise across those three arms, with the highest relapse rate — close to half of patients within the study period — in the group that stopped completely. Tapering to half dose sat in between. That is a genuinely useful result, because it reframes the choice: not "on drugs or off drugs," but a dial you can turn down some distance with a quantified cost.

The conventional order of withdrawal is: glucocorticoids first (they carry the most cumulative harm), then the biologic or JAK inhibitor (usually by increasing the interval between doses or reducing the dose rather than stopping outright), and the conventional DMARD last. Tapering is normally only considered after you have been in sustained remission for at least six to twelve months, and it is done slowly with continued monitoring.

Two things make relapse more likely: remaining seropositive for rheumatoid factor or anti-CCP, and residual inflammation on ultrasound or MRI even when clinical examination looks clean. Those subclinical findings can identify people for whom stopping is a poor bet.

A flare after tapering is usually recoverable — most patients regain control when the previous dose is reinstated — but not always, and the flare itself can cost you joint damage. This is a decision to make deliberately with your rheumatologist, with a defined plan for what happens if symptoms return, rather than by quietly stopping and hoping.

Where Diet, Supplements and Exercise Actually Fit

If you came to this site looking for natural approaches, you were not in the wrong place, and this section is not the part where that gets taken away.

Here is the distinction that resolves most of the tension. Diet, marine omega-3 fatty acids, movement, sleep, smoking cessation, and stress load all measurably influence how inflamed you feel and how much pain medication you need. Several also have plausible and partly demonstrated effects on inflammatory signalling. What has not been shown — despite genuine effort — is that any of them halt the erosive process on serial radiographs. That specific outcome is what DMARDs deliver and what the natural adjuncts do not. It is not a moral judgement about which approach is purer; it is a statement about which intervention has been shown to stop bone disappearing.

Which leaves plenty of room for both:

• Omega-3 fatty acids have the best evidence of the supplements, with consistent findings for reduced morning stiffness, tender joint counts, and NSAID requirement. That is a real benefit worth having alongside a DMARD. See Omega-3 and Fish Oil.
• Dietary pattern matters for the cardiovascular risk that rheumatoid arthritis itself elevates — and cardiovascular disease, not joint destruction, is what shortens life in this condition. See Anti-Inflammatory Diet.
• Exercise preserves the muscle that protects the joint and counteracts steroid-driven bone loss and muscle wasting. See Exercise and Joint Protection.
• Stopping smoking is the single highest-value non-drug intervention in rheumatoid arthritis: smoking raises the risk of developing the disease, worsens its severity, and reduces the response to several of the drugs on this page.
• Herbs deserve honest evaluation one at a time rather than as a category — the three that patients ask about most are set out below, with what the evidence actually supports and what each one can do to you.

Three Herbs Patients Ask About

Each row gives the evidence tier and the documented harm together, because quoting one without the other is how supplements get sold rather than assessed. None of the three has been shown to stop erosions, and none is a substitute for a DMARD.

The wider Herbs section covers these plants in their own right, outside the rheumatoid arthritis context.

Interactions to raise explicitly. Tell your rheumatologist about everything you take, including things you would not think of as drugs. The marine omega-3 doses actually tested in rheumatoid arthritis are high — generally around 2.7 g or more of combined EPA and DHA per day, several times what a typical general-health capsule delivers — and at that level omega-3 has a mild antiplatelet effect. Trials have not shown clinically important bleeding, including in people taking anticoagulants, so this is a disclosure rather than a prohibition: mention it before any surgery or dental extraction, and mention it if you are on warfarin, a direct oral anticoagulant, or a regular NSAID. Separately, any supplement marketed for "immune support" that genuinely stimulates immune function is working directly against a treatment plan designed to do the opposite — again a conversation, not a ban, but it needs to happen.

Questions Worth Asking at Your Appointment

Say this once and then get on with your life: none of this replaces your rheumatologist's judgement about your particular disease. What it can do is make the conversation better. These are the questions that tend to change the outcome:

1. What is my disease activity score today, and what number are we aiming for?
2. When will we next measure it, and what happens if we have not hit the target by then?
3. Am I on the full dose of methotrexate, or is there room to go up before we add anything?
4. Would the subcutaneous form help with the nausea and fatigue I get?
5. How much folic acid am I on — and would more help with these mouth ulcers?
6. Have I had baseline tuberculosis and hepatitis screening, and are my vaccinations up to date before we start a biologic?
7. Given my age, smoking history and cardiovascular risk, where do JAK inhibitors sit for me specifically?
8. What is the plan for getting me off prednisone, and what has to be true first?
9. Is triple therapy an option for me, especially given what a biologic would cost me?
10. If I stay in remission for a year, what would a tapering plan look like, and what would we do if I flared?

Key Research Papers

Every citation below was verified against the Crossref registry before publication. Journal names and titles are plain text; the linked portion is the DOI.

1. van Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Annals of the Rheumatic Diseases. 2014;73(5):861–870.
2. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. The Lancet. 2004;364(9430):263–269.
3. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases. 2016;75(1):16–22.
4. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis & Rheumatism. 2005;52(11):3381–3390.
5. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2014;(6):CD000957.
6. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2013;(5):CD000951.
7. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis & Rheumatism. 2008;58(1):73–81.
8. Humphreys JH, Warner A, Costello R, et al. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases. 2017;76(9):1509–1514.
9. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine. 2013;369(4):307–318.
10. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis & Rheumatism. 2012;64(9):2824–2835.
11. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. The Lancet. 2013;381(9877):1541–1550.
12. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2006;144(12):865–876.
13. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis & Rheumatism. 2006;54(9):2793–2806.
14. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine. 2017;376(7):652–662.
15. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New England Journal of Medicine. 2022;386(4):316–326.
16. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis & Rheumatology. 2014;66(10):2675–2684.
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine. 2001;345(15):1098–1104.
18. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews. 2011;(2):CD008794.
19. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis & Rheumatology. 2023;75(3):333–348.
20. Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases. 2022;81(7):925–936.
21. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Annals of the Rheumatic Diseases. 2016;75(1):45–51.
22. Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2009;151(4):229–240.
23. Lv QW, Zhang W, Shi Q, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Annals of the Rheumatic Diseases. 2015;74(6):1078–1086.
24. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytotherapy Research. 2012;26(11):1719–1725.
25. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):3–18.
26. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2021;73(7):1108–1123.

Live PubMed Searches

These links run a fresh search each time you click them, so they surface work published after this page was written.

1. PubMed: methotrexate in rheumatoid arthritis, randomised trials
2. PubMed: treat-to-target and remission in rheumatoid arthritis
3. PubMed: window of opportunity in early rheumatoid arthritis
4. PubMed: triple therapy in rheumatoid arthritis
5. PubMed: TNF inhibitors and radiographic progression
6. PubMed: IL-6 receptor blockade in rheumatoid arthritis
7. PubMed: abatacept and antibody status in rheumatoid arthritis
8. PubMed: rituximab, B-cell depletion and immunoglobulin levels
9. PubMed: JAK inhibitor cardiovascular and thrombosis safety
10. PubMed: glucocorticoid bridging therapy and its harms
11. PubMed: latent tuberculosis screening before biologics
12. PubMed: vaccine response under immunosuppression
13. PubMed: DMARD tapering and drug-free remission
14. PubMed: omega-3 fatty acids in rheumatoid arthritis
15. PubMed: smoking and treatment response in rheumatoid arthritis

External Resources

• American College of Rheumatology — guidelines and patient drug information sheets.
• EULAR — the European alliance of rheumatology associations and its recommendation series.
• Versus Arthritis — plain-language drug leaflets written for patients.

Connections

• Rheumatoid Arthritis — the canonical overview: diagnosis, antibodies, and disease course
• Anti-Inflammatory Diet — what dietary pattern can and cannot do alongside these drugs
• Omega-3 and Fish Oil — the best-evidenced supplement adjunct
• Exercise and Joint Protection — muscle as joint protection, and steroid-related bone loss
• Turmeric — the most-asked-about herb in inflammatory arthritis, and why its liver signal matters on methotrexate
• Boswellia — strong osteoarthritis reputation, thin rheumatoid arthritis evidence
• Shoulder Involvement — what happens when the disease reaches a large joint
• Rheumatology — the full category of rheumatic and autoimmune conditions
• Ankylosing Spondylitis — a related disease where TNF inhibitors are also central
• Arthritis — how inflammatory arthritis differs from wear-and-tear osteoarthritis
• Folate (Vitamin B9) — the vitamin methotrexate works against, and why supplementation matters
• Vitamin D — bone protection during any long corticosteroid course
• Calcium — the other half of steroid-related bone protection
• Nephrology & Hepatology — why liver and kidney health shape methotrexate and leflunomide decisions
• Lab Tests — the blood work behind diagnosis and drug monitoring

↑ Back to Table of Contents

Featured Videos